Literature DB >> 21563994

Cognitive behavior therapy for schizophrenia: a meta-analytical review of randomized controlled trials.

Freddy Sarin1, Lennart Wallin, Birgitta Widerlöv.   

Abstract

BACKGROUND: In the UK and in Sweden, cognitive behavior therapy (CBT) has been recommended for schizophrenia. The two recent meta-analyses examined results soon after treatment and not at follow-up. AIM: To determine the effectiveness of CBT in people with schizophrenia, both after treatment and at follow-up, and to compare it with treatment as usual (TAU) and other psychological treatments.
METHODS: The search was carried in the databases CENTRAL (Cochrane Central Register of Controlled Trials), PsycINFO and PubMed (Medline). Inclusion criteria were randomized controlled trials (RCTs) with low risk of bias. Two reviewers, working independently, extracted data. The results were analyzed using risk ratio (RR), risk difference (RD), mean difference (MD), or standardized mean difference (SMD). Outcome measures were symptoms, use of medication, relapse and clinically important improvement.
RESULTS: When CBT was compared with other psychological treatments at follow-up, there was strong evidence (with small treatment effect) that intervention has an effect with positive symptoms (P = 0.02), negative symptoms (P = 0.03) and general symptoms (P = 0.003). After treatment, there was a trend in favor of CBT, but not statistically significantly so.
CONCLUSION: It appears that the effect of CBT is delayed; it could be seen a few months after the treatment had terminated. Therapies for patients with schizophrenia that were 20 sessions long or more had better outcomes than those that were shorter.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21563994     DOI: 10.3109/08039488.2011.577188

Source DB:  PubMed          Journal:  Nord J Psychiatry        ISSN: 0803-9488            Impact factor:   2.202


  25 in total

Review 1.  Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.

Authors:  Selene R T Veerman; Peter F J Schulte; Lieuwe de Haan
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

2.  [The CIMH track concept in the treatment of psychotic disorders].

Authors:  Dusan Hirjak; Peter Gass; Michael Deuschle; F Markus Leweke; Andreas Böhringer; Nadine Schenkel; Doris Borgwedel; Marco Heser; Antje Breisacher; Andreas Meyer-Lindenberg
Journal:  Nervenarzt       Date:  2020-03       Impact factor: 1.214

Review 3.  Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives.

Authors:  Frederick C Nucifora; Edgar Woznica; Brian J Lee; Nicola Cascella; Akira Sawa
Journal:  Neurobiol Dis       Date:  2018-08-29       Impact factor: 5.996

4.  The Influence of Causal Explanations and Diagnostic Labeling on Psychology Students' Beliefs About Treatments, Prognosis, Dangerousness and Unpredictability in Schizophrenia.

Authors:  Lorenza Magliano; John Read; Angela Rinaldi; Regina Costanzo; Renata De Leo; Giustina Schioppa; Miriam Petrillo
Journal:  Community Ment Health J       Date:  2015-06-17

5.  Efficacy and acceptability of psychosocial interventions in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence.

Authors:  Marco Solmi; Giovanni Croatto; Giada Piva; Stella Rosson; Paolo Fusar-Poli; Jose M Rubio; Andre F Carvalho; Eduard Vieta; Celso Arango; Nicole R DeTore; Elizabeth S Eberlin; Kim T Mueser; Christoph U Correll
Journal:  Mol Psychiatry       Date:  2022-08-23       Impact factor: 13.437

6.  [Guideline-conform psychiatric psychotherapeutic treatment for patients with schizophrenia : A normative evaluation of necessary personnel requirements].

Authors:  S Mehl; P Falkai; M Berger; M Löhr; D Rujescu; J Wolff; T Kircher
Journal:  Nervenarzt       Date:  2016-03       Impact factor: 1.214

7.  Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials.

Authors:  Paolo Fusar-Poli; Evangelos Papanastasiou; Daniel Stahl; Matteo Rocchetti; William Carpenter; Sukhwinder Shergill; Philip McGuire
Journal:  Schizophr Bull       Date:  2014-12-20       Impact factor: 9.306

8.  From epidemiology to daily life: linking daily life stress reactivity to persistence of psychotic experiences in a longitudinal general population study.

Authors:  Dina Collip; Johanna T W Wigman; Inez Myin-Germeys; Nele Jacobs; Catherine Derom; Evert Thiery; Marieke Wichers; Jim van Os
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

9.  Sensorimotor gating and clinical outcome following cognitive behaviour therapy for psychosis.

Authors:  Veena Kumari; Preethi Premkumar; Dominic Fannon; Ingrid Aasen; Satya Raghuvanshi; Anantha P Anilkumar; Elena Antonova; Emmanuelle R Peters; Elizabeth Kuipers
Journal:  Schizophr Res       Date:  2011-12-03       Impact factor: 4.939

Review 10.  Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment.

Authors:  Mathias Zink
Journal:  Adv Med       Date:  2014-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.